NASH

In 2020, Saroglitazar Mg received approval for the treatment of NASH and NAFLD

HepaStem is a stem cell therapy consisting of liver-derived mesenchymal stem cells (MSC) that addresses different components of…

Currently, Madrigal’s resmetirom (selective thyroid hormone receptor-β agonist; THR-Beta agonist) will most likely be the first…

Phase IV EVIDENCES- XI trial will enroll approximately 1500 NAFLD patients with comorbidities

Triple combination regimen to be investigated in new Phase 2b study in NASH patients with cirrhosis

Saroglitazar Mg is already approved for the treatment of type-2 diabetes and NASH

The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029

In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis

NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for…